Stanford University to Study Pathwork's Diagnostic Test
Posted on: Wednesday, 7 May 2008, 12:01 CDT
Pathwork Diagnostics has announced that the Stanford University School of Medicine has initiated an investigational study of the Pathwork Tissue of Origin Test.
The new test uses advanced genomics-based technology to help physicians determine a tumor's origin in order to optimize cancer-specific treatment. The study will evaluate the test's ability to impact diagnosis for cancer patients with hard-to-identify tumors, with test samples processed at the Stanford University School of Medicine's laboratory.
The Pathwork Tissue of Origin Test measures the expression of more than 1,500 genes to compare a tumor's gene expression profile to those of 15 known tissues, representing more than 60 morphologies, and to provide a report with an objective, probability-based score for each potential tissue. This helps physicians rule in and rule out potential tissue types.
Deborah Neff, Pathwork Diagnostic's president and CEO, said: "Our test is available as a service through our CLIA-certified laboratory so that physicians outside of Stanford University can have specimens processed and clinical results provided. Additionally, we are actively working to obtain FDA clearance so that we can offer a diagnostic kit directly to clinical laboratories at major medical centers."
Source: Datamonitor
Related Articles
- Canary Foundation and Stanford University Commit $20 Million for World-Class Research Center for Cancer Early Detection
- Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
- Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
- Stanford University and Veterans Affairs Researchers Demonstrate Significant Glucose Reduction in Study of CVAC Process for Insulin Resistance and Diabetes
- FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
- Stanford University to Study Genomics-Based Diagnostic Test for Uncertain Tumors
- Canary Foundation and Stanford University Announce Center of Excellence for Cancer Early Detection
- Presidio Pharmaceuticals Receives Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
- Stem Cell Innovations Signs Material Transfer Agreement to Supply PluriCells(TM) to Stanford University Researchers
User Comments (0)

RSS Feeds